Today: 29 June 2026
Browse Category

NYSE:AZN 16 September 2025 - 7 February 2026

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

London, Feb 1, 2026, 18:57 GMT — Markets have shut for the day. AstraZeneca announced its ordinary shares are set to begin trading on the New York Stock Exchange this Monday, following the withdrawal of its American depositary shares — the vehicle for U.S. trading — from Nasdaq. The company confirmed the AZN ticker will stay the same, with shares continuing to trade on the London Stock Exchange and Nasdaq Stockholm.
1 February 2026
···
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

New York, Jan 31, 2026, 13:49 EST — Market closed. Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
31 January 2026
······
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

London, January 24, 2026, 19:48 GMT — Markets have closed A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and several major drug and medical-device companies of funneling millions in cash and medical supplies to fund terrorism in Iraq. The plaintiffs claim the firms made corrupt payments to Jaysh al‑Mahdi, a militia backed by Hezbollah, to win contracts from the Iraqi Health Ministry. They are seeking unspecified damages under the U.S. Anti‑Terrorism Act.
24 January 2026
··
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

New York, Jan 12, 2026, 05:29 EST — Premarket Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27.
12 January 2026
·······
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

LONDON, Dec. 7, 2025 — The MSCI Europe Index slipped modestly at the end of the week but remains one of 2025’s equity standouts, still ahead of broad global benchmarks such as the MSCI World and MSCI ACWI. European stocks are pausing after a powerful rally, even as fresh forecasts from major banks signal further upside into 2026 and technical indicators continue to lean constructive. At Friday’s close on 5 December 2025, the MSCI Europe Index finished at 2,564.76, down 0.25% on the day after three sessions of gains. Investing.com
7 December 2025
···········
Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce has triggered a fresh wave of headlines after posting record third‑quarter fiscal 2026 results, raising its full‑year outlook and signing a high‑profile AI deal with AstraZeneca. Yet despite the post‑earnings stock pop and new enterprise wins, CEO Marc Benioff is still fighting to convince Wall Street that Salesforce’s aggressive artificial intelligence strategy will translate into lasting shareholder returns. Salesforce Investor Relations+2Reuters+2 For its fiscal third quarter ended October 31, 2025, Salesforce reported:
5 December 2025
·····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA, the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca. As of mid‑afternoon U.S. trading on Thursday, November 20, 2025, ABVX stock is trading around $121.94, up roughly 8% from Wednesday’s close of $112.95. Intraday, shares have ranged between about $113.63 and $126.42, on heavy volume of roughly 3.7 million American Depositary Shares. Stock Invest
20 November 2025
··
Nasdaq Rally Amid Tech Frenzy: Markets Brush Off Shutdown Fears in Late September 2025

U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus

Here’s your fast, fact‑checked brief on what matters before the bell in the U.S. today. Why it matters: Claims set the tone for labor‑market momentum; productivity and labor‑costs feed the inflation outlook that informs the Fed’s rate‑cut path into year‑end. Reuters
6 November 2025
········
Stocks Rally to Record Highs as Shutdown Looms – Dow and S&P Post Best September in 15 Years

Stocks to Buy Today (Nov 6, 2025): ARM, AppLovin, Qualcomm, Tesla, Snap, AstraZeneca, Airbnb & More

Published: November 6, 2025 — This article curates today’s biggest catalysts and the most interesting stocks to consider, with fresh data and sources. Not financial advice. Below are 10 names with fresh catalysts on Thursday, November 6, 2025. For each, we summarize the why now, the key numbers from today’s news flow, and what to watch next.
6 November 2025
·······
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% reuters.com. France’s CAC 40 and Germany’s DAX each gained a few tenths of a percent reuters.com. Major indices in Southern Europe also edged up. Across sectors, the strongest gains were in healthcare and tech, offsetting weakness in commodity-linked areas and automakers. Several high-profile company announcements drove individual stocks on Monday. In pharmaceuticals, GSK jumped ~3.5% after announcing that long-time CEO Emma Walmsley will step down at year-end, handing over to COO Luke Miels reuters.com. A market commentator noted GSK shares had been lagging peers, and the new leadership “is a bet the market likes for now” standard.co.uk. AstraZeneca also moved higher when it said it will list ordinary shares directly in New York to attract more US investors, while keeping its London and Stockholm listings reuters.com. CEO Pascal Soriot and CFO Chris Demarest emphasized the change “will allow us to reach a broader mix of global investors” reuters.com.
29 September 2025
·······
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m, core +0.2% m/m. Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print. Reuters “This should give some reassurances on the inflation side,” said Doug Beath of Wells Fargo Investment Institute. Reuters
26 September 2025
·······
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will include over 200,000 square feet of production space Virginiabusiness, equipped with cutting-edge technologies like machine learning, artificial intelligence, and automation to ensure precision and efficiency Prnewswire. Construction is beginning immediately and expected to take about five years to fully complete Washingtonpost – a timeline Lilly hopes to beat if possible, according to CEO David “Dave” Ricks Virginiabusiness. Initial site work and permitting are starting within weeks, and Lilly aims to have the physical plant built in about three years, then undergo equipment validation and regulatory approvals Virginiabusiness. “The typical timeline…is five years…so we’d like to beat that,” Ricks said, noting Lilly is working with federal regulators to speed up
16 September 2025
·······
Go toTop